Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine

Coulter, A.R.; Harris, Rodney; Davis, Roslyn; Drane, Debbie; Cox, John C.; Ryan, David; Sutton, Philip; Rockman, Steve; Pearse, Martin J.

doi:10.1016/s0264-410x(02)00545-5

Cited by 97 publications

(48 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Feed and water were supplied ad libitum . In this experiment, recombinant FimH156 was combined with the Iscomatrix adjuvant (Bengtsson & Sjö lander, 1996;Windon et al , 2000;Coulter et al , 2003) and tested as a parenteral or mucosal vaccine. At 10 days of age (0 d.p.v.…”

Section: Methodsmentioning

confidence: 99%

Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenicEscherichia coli

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenicEscherichia coli

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Today, mucosal administration in domestic animals is still limited. Intranasal immunization has been performed in pigs against rotavirus [80], in sheep against influenza hemagglutinin [39] and in dogs against Echinococcus granulosus surface antigens or ovalbumin [26]. In all three studies, an enhanced mucosal IgA response was observed.…”

Section: Antigen-presenting Cell Targeting Mucosal Adjuvantsmentioning

confidence: 99%

“…This adjuvant can be mixed with antigens and when applied at a mucosa should have some of the advantages of ISCOM such as the preferential targeting of antigen presenting cells. The ISCOMATRIX has been analyzed in oral [209] and intranasal immunization in sheep [39] and in oral immunization in pigs [96] and it induced good mucosal IgA responses. However, the response obtained in sheep differed from that of an ISCOM vaccination in that the ISCOMATRIX induced a Th2-like response, whereas the ISCOM vaccine induced a mixed Th1-/Th2-like response.…”

Section: Antigen-presenting Cell Targeting Mucosal Adjuvantsmentioning

confidence: 99%

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

et al. 2006

View full text Add to dashboard Cite

-In developing veterinary mucosal vaccines and vaccination strategies, mucosal adjuvants are one of the key players for inducing protective immune responses. Most of the mucosal adjuvants seem to exert their effect via binding to a receptor/or target cells and these properties were used to classify the mucosal adjuvants reviewed in the present paper: (1) ganglioside receptor-binding toxins (cholera toxin, LT enterotoxin, their B subunits and mutants); (2) surface immunoglobulin binding complex CTA1-DD; (3) TLR4 binding lipopolysaccharide; (4) TLR2-binding muramyl dipeptide; (5) Mannose receptor-binding mannan; (6) Dectin-1-binding ß 1,3/1,6 glucans; (7) TLR9-binding CpG-oligodeoxynucleotides; (8) Cytokines and chemokines; (9) Antigen-presenting cell targeting ISCOMATRIX and ISCOM. In addition, attention is given to two adjuvants able to prime the mucosal immune system following a systemic immunization, namely 1α, 25(OH) 2 D 3 and cholera toxin.

show abstract

“…A large number of alternatives to inactivated influenza vaccines have been studied, including recombinant proteins [7,8], poxvirus vectors [9], DNA vaccines [10], immunostimulatory complexes [11], proteosome vaccines [12] and live attenuated vaccines [13,14]. In the present study, we describe the construction, process development and preclinical evaluation of a propagation-defective, single-cycle, alphavirus replicon vaccine for influenza that is suitable for clinical testing.…”

Section: Introductionmentioning

confidence: 99%

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

Hubby

Talarico

Maughan

et al. 2007

Vaccine

View full text Add to dashboard Cite

We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce viruslike replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-γ ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.

show abstract

Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine

Cited by 97 publications

References 6 publications

Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenicEscherichia coli

Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenicEscherichia coli

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

Contact Info

Product

Resources

About